Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which
aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in
platinum-resistant recurrent ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine